Global Chikungunya Treatment Market - Industry Trends and Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Sep 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Chikungunya Treatment Market By Strain Type (Aedes Aegypti, Aedes Albopictus), Treatment (Medication, Vaccination), Drug Class (Analgesics, Antipyretics, Vaccines and Others), Drugs (Acetaminophen, Dengvaxia and Others), Route of Administration (Oral and Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), End-Users (Hospitals, Homecare, Specialty Clinics and Others), Geography (North America, Europe, Asia-Pacific, South America, Middle East and Africa) - Industry Trends and Forecast to 2026

Market Analysis: Global Chikungunya Treatment Market

Global chikungunya treatment market is growing at a substantial CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the increasing prevalence of dengue in tropical and sub-tropical regions, increased government funding to fight against dengue, unmet market needs of managing dengue burden around the world and rise in investment from government, public & private organizations for the development of novel drugs.

Market Definition: Global Chikungunya Treatment Market

Chikungunya virus infection is also known as chikungunya fever is characterized by mosquito-borne viral disease which is spread by a bite of an infected Aedes species mosquito including aedes aegypti and aedes albopictus. The most common symptoms of infection are fever and joint pain.

According to statistics published in the WHO, it was estimated a total of 349,936 suspected and 146,914 laboratory confirmed cases of chikungunya has been reported to the PAHO regional office. Of these, 265, 000 suspected cases were locally reported from the Brazil. The market growth is increased by introduction of novel therapies and rise in government initiatives may increase the chikungunya virus infection drug market.

Market Drivers

  • Increasing prevalence of chikungunya in tropical and sub-tropical regions is driving the market growth.
  • Increased government funding to fight against chikungunya is accelerating the market growth
  • Promising chikungunya pipeline is expected to drive the market growth
  • Demand of novel therapies for treating chikungunya virus infections is also acting as a driver for the market

Market Restraints

  • Lack or insufficient healthcare infrastructure in underdeveloped and developing regions is hampering the market growth
  • Lack of awareness related to symptoms of chikungunya is hindering the market growth
  • High cost of the treatment is restraining the market growth.

Segmentation: Global Chikungunya Treatment Market

By Strain Type

  • Aedes Aegypti
  • Aedes Albopictus

By Treatment

  • Medication
  • Vaccination

By Drug Class

  • Analgesics
  • Antipyretics
  • Vaccines
  • Others

By Drugs

  • Acetaminophen
  • Dengvaxia
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By End-Users

  • Hospitals
  • Homecare
  • Specialty Clinics

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • Europe

    • Germany
    • Italy
    • U.K.
    • France
    • Spain
    • Netherlands
    • Belgium
    • Switzerland
    • Turkey
    • Russia
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Singapore
    • Malaysia
    • Thailand
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • South America

    • Brazil
    • Rest of South America

  • Middle East & Africa

    • South Africa
    • Rest of Middle East & Africa

Key Developments in the Market

  • In February 2019, Moderna, Inc, has initiated first dose in patients in a phase I clinical trial for mRNA-1944, an anti-Chikungunya antibody for the treatment of chikungunya virus infections. The dosing of first monoclonal antibody encoded by mRNA in human subject is a significant milestone for a company and represents advances in the novel treatment through targeted mode of action.
  • In February 2019, Themis Bioscience GmbH received the fast track designation from the FDA for MV-CHIK, a vaccine for the treatment of chikungunya viral infections. The Fast Track designation for MV-CHIK accelerates the review timeline and enhances the attraction with the FDA so that lead candidate can reach the market expeditiously.
  • In September 2016, Takeda Pharmaceutical Company Limited entered into research collaboration with Zydus Cadila to develop a novel vaccine for the treatment of chikungunya virus infection. This collaboration will address the urgent and neglected unmet medical need as well as expedite the access to novel treatment options for patients suffering from chikungunya.

Competitive Analysis:

Global chikungunya treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of chikungunya treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

The key market players in the global chikungunya treatment market are Themis Bioscience GmbH, Arno Therapeutics, Inc, Bharat Biotech, Paradigm Biopharmaceuticals Ltd, Nano Therapeutics Pvt Ltd, Hawaii Biotech Inc, Indian Immunologicals Limited, Inovio Pharmaceuticals, Inc., Integral Molecular, Integrated BioTherapeutics, Inc, Mapp Biopharmaceautical, Moderna, Inc., MYMETICS, Zydus Cadila, Takeda Pharmaceutical Company Limited and others

Research Methodology: Global Chikungunya Treatment Market:

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents:

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technical Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report:

  • Current and future of global chikungunya treatment market outlook in the developed and emerging markets.
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period.
  • The latest developments, market shares, and strategies that are employed by the major market players.


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19